In a murine model, the neutralization of soluble NKG2D ligands such as MICA and MICB with mAb B10G5 was effective against prostate carcinoma and metastasis, leading to the enhanced NK cell infiltration in the tumor parenchyma (163), and improving CTLA-4 blockade therapy (164). The gene discussed is KLRK1; the disease is neoplasm.